Y-MABS THERAPEUTICS INC. - COMMON STOCK

Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer

14 Mar 2024 09:05:00 By Nasdaq GlobeNewswire

Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors

04 Mar 2024 07:30:00 By Nasdaq GlobeNewswire

Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments

29 Feb 2024 16:05:00 By Nasdaq GlobeNewswire

Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024

16 Feb 2024 07:30:00 By Nasdaq GlobeNewswire

Y-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

02 Jan 2024 16:05:00 By Nasdaq GlobeNewswire

Y-mAbs Therapeutics Added to the NASDAQ Biotechnology Index

13 Dec 2023 16:05:00 By Nasdaq GlobeNewswire

Y-mAbs Reports Third Quarter 2023 Financial Results and Recent Corporate Developments

13 Nov 2023 16:05:00 By Nasdaq GlobeNewswire

Y-mAbs to Announce Third Quarter 2023 Financial and Operating Results on November 13, 2023

31 Oct 2023 07:05:00 By Nasdaq GlobeNewswire

Y-mAbs Names Michael Rossi as President and Chief Executive Officer and Director

18 Oct 2023 16:05:00 By Nasdaq GlobeNewswire

Y-mAbs Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for CD38-SADA

17 Oct 2023 16:05:00 By Nasdaq GlobeNewswire

Y-mAbs Announces Publication in Cancers

16 Oct 2023 16:05:00 By Nasdaq GlobeNewswire

Y-mAbs Announces Data to be Presented at the 55th Congress of the International Society of Pediatric Oncology

21 Sep 2023 16:05:00 By Nasdaq GlobeNewswire

Y-mAbs to Participate at Upcoming Investor Conferences in September

06 Sep 2023 16:05:00 By Nasdaq GlobeNewswire

Y-mAbs Reports Second Quarter 2023 Financial Results and Recent Corporate Developments

10 Aug 2023 16:05:02 By Nasdaq GlobeNewswire

Y-mAbs to Participate at Upcoming Investor Conferences

02 Aug 2023 16:05:00 By Nasdaq GlobeNewswire

Y-mAbs to Announce Second Quarter 2023 Financial and Operating Results on August 10, 2023

01 Aug 2023 16:05:00 By Nasdaq GlobeNewswire

Y-mAbs Announces Presentation of GD2-SADA Study at ASCO

26 May 2023 09:00:00 By Nasdaq GlobeNewswire

Y-mAbs Announces Presentation of Naxitamab Data at ASCO

26 May 2023 09:00:00 By Nasdaq GlobeNewswire

Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma approved in Brazil

23 May 2023 09:00:00 By Nasdaq GlobeNewswire

Y-mAbs Reports First Quarter 2023 Financial Results and Recent Corporate Developments and Updates 2023 Financial Guidance

08 May 2023 16:01:00 By Nasdaq GlobeNewswire